Physician profile
John Chaney
NPI 1134447816
$2,230.69
in general payments reported to CMS, 2019-2025
19 companies · $819 in 2025
The $819 reported for 2025 was more than what 76% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $37.41 · 2022: $242 · 2023: $644 · 2024: $488 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,951.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,951.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $406.47 | 2021-2025 | Caplyta |
| Abbvie INC. | $325.60 | 2022-2025 | |
| Supernus Pharmaceuticals, INC. | $208.71 | 2023-2025 | Qelbree, Qelbree |
| Otsuka America Pharmaceutical, INC. | $202.73 | 2022-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $177.85 | 2024-2025 | Ingrezza |
| Lundbeck LLC | $162.38 | 2022-2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $141.84 | 2024-2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $112.83 | 2021-2025 | Uzedy, Austedo |
| Takeda Pharmaceuticals U.S.A., INC. | $90.72 | 2023-2025 | Trintellix |
| Axsome Therapeutics, INC. | $81.22 | 2023-2025 | Auvelity |
| Alkermes, INC. | $72.88 | 2023-2024 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $72.77 | 2022-2025 | Invega Sustenna |
| Indivior INC. | $34.95 | 2023-2025 | Sublocade, Perseris |
| Exact Sciences Corporation | $34.35 | 2024-2025 | Cologuard Collection Kit |
| Collegium Pharmaceutical, INC. | $31.38 | 2025 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $26.03 | 2022 | |
| Ironshore Pharmaceuticals INC. | $19.54 | 2024 | |
| Tris Pharma INC | $14.90 | 2023 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $13.54 | 2025 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Chaney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.